Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002026 · ClinicalTrials.gov registry record · NA
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002026 is a NA study that has completed, run by Glaxo Wellcome.
The verdict
NCT00002026, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.
Interventions
- DRUG Acyclovir
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002026
The ClinicalTrials.gov registry entry for NCT00002026 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acyclovir is the first listed.
NCT00002026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002026 about?
NCT00002026 is a clinical study titled "Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)". To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and c...
What is the current status of trial NCT00002026?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002026?
The interventions under investigation include: Acyclovir (DRUG).
Who is sponsoring clinical trial NCT00002026?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.